Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure

Background: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce mortality and morbidity in patients with heart failure (HF), but are discontinued in some patients. Such patients may not enjoy favorable benefits of SGLT2i therapy. We evaluated the risk factors for SGLT2i discontinuation in a re...

Full description

Bibliographic Details
Main Authors: Masaki Nakagaito, Teruhiko Imamura, Ryuichi Ushijima, Makiko Nakamura, Koichiro Kinugawa
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/11/3/876